{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:09Z","timestamp":1750538409045,"version":"3.41.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 71-year-old man with a history of carcinoid and prostate adenocarcinoma underwent <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT to evaluate new mediastinal lymphadenopathy. The scan revealed new carcinoid metastases, but the mediastinal nodes were not avid. <jats:sup>18<\/jats:sup>F-FDG PET\/CT was performed to evaluate for cardiac and mediastinal sarcoidosis, revealing a lack of cardiac sarcoidosis, but probable mediastinal sarcoidosis. <jats:sup>18<\/jats:sup>F-Fluciclovine PET\/CT was then performed for possible prostate metastases, revealing the patient\u2019s known prostate cancer. Three different PET radiopharmaceuticals revealed 3 different processes in a single patient within a 195-day period, demonstrating the power of nuclear medicine diagnostics.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003853","type":"journal-article","created":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T22:02:23Z","timestamp":1629064943000},"page":"e161-e164","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The \u201cUltimate Triple PET\u201d"],"prefix":"10.1097","volume":"47","author":[{"given":"Matthew","family":"McClenathan","sequence":"first","affiliation":[{"name":"Department of Radiology, Brooke Army Medical Center, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin G.","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2967\/jnumed.116.186361","article-title":"Current concepts in 68Ga-DOTATATE imaging of neuroendocrine neoplasms: interpretation, biodistribution, dosimetry, and molecular strategies","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","article-title":"Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The impact of 68Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a National Referral Center in the United Kingdom","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.1365-2362.1999.00498.x","article-title":"Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas","volume":"29","year":"1999","journal-title":"Eur J Clin Invest"},{"journal-title":"J Nucl Cardiol","article-title":"Benefits of [68Ga]-DOTATATE PET-CT comparable to [18F]-FDG in patient with suspected cardiac sarcoidosis","year":"2020","key":"bib5-20250621"},{"key":"bib6-20250621","first-page":"1989","article-title":"Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis","volume":"45","year":"2004","journal-title":"J Nucl Med"},{"key":"bib7-20250621","first-page":"1647","article-title":"Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis","volume":"35","year":"1994","journal-title":"J Nucl Med"},{"key":"bib8-20250621","first-page":"1571","article-title":"Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis","volume":"47","year":"2006","journal-title":"J Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/MNM.0000000000001051","article-title":"Comparison of 18F-Fluciclovine PET\/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer","volume":"40","year":"2019","journal-title":"Nucl Med Commun"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/RLU.0000000000002130","article-title":"Diagnostic performance of 18F-Fluciclovine in detection of prostate cancer bone metastases","volume":"43","year":"2018","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:07:19Z","timestamp":1750536439000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003853"}},"subtitle":["68Ga-DOTATATE, 18F-FDG, and 18F-Fluciclovine PET\/CT Findings in a Single Patient With Metastatic Abdominal Carcinoid and Prostate Cancer"],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003853","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}